Research as a bridge between clinical evidence, artificial intelligence and global care.
Context
At a time when artificial intelligence (AI) is redefining clinical diagnostics and prevention, interdisciplinary research is crucial to implement technologies safely, effectively, and ethically.
As a physician, scientist and MBA graduate, Dr. Amr Saad combines medical precision with economic thinking. His international research projects – from Europe to Switzerland to the United Arab Emirates and the USA – combine clinical ophthalmology, algorithmic prevention and system efficiency..
Details
Time frame:
since 2023
Role:
Author, Reviewer
Participation:
Scientific Activity
Overview
Amr Saad works in international research collaborations on refractive surgery, oculomics, AI risk prevention and applied patient education, including with institutions such as the Bascom Palmer Eye Institute (USA), Swiss Retina Groups (Zurich), DOG/DOC (Germany), ESO/EPOMEC (UAE) and other partners in Europe and the Middle East.
Challenge
Many digital health technologies fail not because of the technology itself, but because of the lack of scientific foundation and clinical validation..
At the same time, research and implementation often run separately – publications here, product development there, without structural transfer.
Solution
Dr. Saad is working on research that integrates implementation intelligence..
Seine Projekte folgen einem klaren Dreiklang:
- Evidence-based: Multicenter data analysis and clinical studies on the safety and precision of refractive procedures.
- Technology integration: Application of deep learning in the early detection of ophthalmological and systemic diseases.
- Systemic transfer: Development of frameworks that anchor AI as a prevention and cost-cutting tool in insurance and hospital systems.
The result is scalable research results that do not end in the laboratory, but transition into real care pathways.
Results
Dr. Saad's publications and international collaborations are already having a measurable impact:
17 times cited publication on SMILE Pro (VisuMax 800) – Proof of higher precision and safety.
Largest Global Analysis on the Angle KappaIssue in MIOL Patients – Improving Patient Selection and Postoperative Vision Quality.
AI Adoption Study (Switzerland, 2024): Shows high acceptance of AI in explainable systems and forms the basis for educational concepts in ophthalmology.
MBA project "AI in Prevention": Empirical study with health insurance and hospital representatives on opportunities, data protection and model transparency – Result: Guidelines for pilot apps for risk prediction and cost reduction.
These projects combine science, ethics and business – as a blueprint for predictive, sustainable medicine..